Bibliography
- EvaluatePharma World Preview 2014, Outlook to 2020 [Internet]. 2014. Available from: http://www.evaluategroup.com/public/reports/EvaluatePharma-World-Preview-2014.aspx [Last accessed 15 April 2015]
- Tufts Center for the Study of Drug Development. Innovation in the Pharmaceutical Industry: New Estimates of R&D Costs [Internet]. 2014. Available from: http://csdd.tufts.edu/news/complete_story/cost_study_press_event_webcast [Last accessed 18 April 2015]
- Daidoji K, Yasukawa S, Kano S. Effects of new formulation strategy on life cycle management in the US pharmaceutical industry. J Generic Med Bus 2014;1741134314543127
- Manso PJ, Sokol AL. Life cycle management of aging pharmaceutical assets. Pharm Law Insight 2007;3(7):16-19
- Ellery T, Hansen N. Pharmaceutical lifecycle management: making the most of each and every brand. 1st edition. Wiley; Hoboken: 2012. p. 143-51
- Dubey R, Dubey J. Pharmaceutical product differentiation: a strategy for strengthening product pipeline and life cycle management. J Med Mark Device Diagn Pharm Mark 2009;9(2):104-18
- Lindberg P, Keeling D, Fryklund J, et al. Review article: Esomeprazole–enhanced bio-availability, specificity for the proton pump and inhibition of acid secretion. Aliment Pharmacol Ther 2003;17(4):481-8
- Gellad WF, Choi P, Mizah M, et al. Assessing the chiral switch: approval and use of single-enantiomer drugs, 2001 to 2011. Am J Manag Care 2014;20(3):e90-7
- Kapczynski A, Park C, Sampat B. Polymorphs and prodrugs and salts (Oh My!): an empirical analysis of “secondary” pharmaceutical patents. PLoS One 2012;7(12):e49470
- Gilead sciences announces fourth quarter and full year 2014 financial results [Internet]. Available from: http://www.gilead.com/news/press-releases/2015/2/gilead-sciences-announces-fourth-quarter-and-full-year-2014-financial-results [Last accessed 20 April 2015]
- Epzicom/Kivexa [Internet]. Available from: https://www.evaluategroup.com/View/19391--1002-modData/product/epzicom.kivexa [Last accessed 20 April 2015]
- Guidance for industry: new chemical entity exclusivity determinations for certain fixed - combination drug products [Internet]. Available from: http://www.fda.gov/downloads/drugs/guidancecomplianceregulatoryinformation/guidances/ucm386685.pdf [Last accessed 22 April 2015]
- Gaffney A. FDA changes policy hours before approvals, giving companies gift potentially worth billions [Internet]. Available from: http://www.raps.org/Regulatory-Focus/News/2014/10/13/20549/FDA-Changes-Policy-Hours-Before-Approvals-Giving-Companies-Gift-Potentially-Worth-Billions/ [Last accessed 30 April 2015]
- OTC Pharmaceuticals. Global industry guide [Internet]. Available from: http://www.datamonitor.com/store/Product/otc_pharmaceuticals_global_industry_guide?productid=ML00016-322 [Last accessed 30 April 2015]
- Lifecycle management excellence: high-performing strategies used to maximize potential of mature brands [Internet]. Available from: http://www.best-in-class.com/bestp/domrep.nsf/products/494500E3677492E6852579CE007519F3?opendocument [Last accessed 20 May 2015]
- Pay-For-Delay: how drug company pay-offs cost consumers billions: a federal trade commission staff study federal trade commission [Internet]. Available from: https://www.ftc.gov/reports/pay-delay-how-drug-company-pay-offs-cost-consumers-billions-federal-trade-commission-staff [Last accessed 4 August 2015]
- FTC Staff Issues FY 2013 report on branded drug firms’ patent settlements with generic competitors federal trade commission [Internet]. Available from: https://www.ftc.gov/news-events/press-releases/2014/12/ftc-staff-issues-fy-2013-report-branded-drug-firms-patent [Last accessed 4 August 2015]